Bio equivalence Study of Two Capsule Formulations of Omeprazole in Healthy Volunteers

Abstract

The study was conducted in order to assess the bioequivalence of two capsule formulations (test and reference) containing 20 mg of omeprazole (5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl]-lH-benzimidazole, CAS 73590-58-6). Fifty healthy male and female volunteers were treated in a single-centre, randomised, repeated-dose (once daily for six consecutive days), open-label, two-way crossover study, with a washout period of at least 9 days between treatments. Plasma samples were collected up to 12 h post-dosing for the determination of omeprazole by HPLC with photodiode array detector (DAD).

The evaluation of bioequivalence was based on the following pharmacokinetic parameters that were calculated by standard non-compartmental methods: area under the plasma concentration-time curve from zero to the time of the last quantifiable concentration (AUC_t) and that extrapolated to infinity (AUC) and the maximum observed concentration (C_max). The 90% confidence interval around the ratios (test/reference) (obtained by analysis of variance, ANOVA) were 0.92-1.04 for C_max, 0.88-1.05 for AUC_t, and 0.88-1.05 for AUC, i.e., within the predefined acceptable range for the conclusion of bioequivalence. The study indicated that the test and reference formulations containing 20 mg of omeprazole are bioequivalent in terms of both the rate and extent of bioavailability.

Key words

CAS 73590-58-6 - Omeprazole, bioequivalence, pharmacokinetics - Proton pump inhibitors

• References

• 1 Katz PO, Scheiman JM, Barkun AN. [Review article] Acid-related disease -what are the unmet clincal needs?. Aliment Pharmacol Ther. 2006; 23 Suppl (2) 9-22
• 2 Sachs G, Shin JM, Howden CW. [Review article] The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23 Suppl (2) 2-8
• 3 Richards JP, Gimeno M, Moreland TA, McEwen J. A relative bioavailability study of 2 oral formulations of omeprazole after their administration in repeated doses to healthy volunteers. Gastroenterol Hepatol. 1999; Apr 22 (4) 171-5
• 4 The European Agency for the Evaluation of Medicinal Products. Note for guidance on the investigation of bioavailability bioequivalence. London. 26 July 2001. CPMP/EWP/QWP/1401.
• 5 Wynn GH, Sandson NB, Cozza KL. Gastrointestinal Medication. Psychosomatics. 2007; 48 (1) 79-85
• 6 World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subject. 52nd WMA General Assembly Edinburgh, Scotland. October 2000.
• 7 European Agency for the Evaluation of Medicinal Products. Note for Guidance on Good Clinical Practice. July 2002. CPMP/ICH/135/95.
• 8 Guidance for Industry. Bioanalytical Method Validation U.S. Department of Health and Human Services. Food and Drug Administration. May 2001.
• 9 Farinha A, Bica A, Pais JP, Toscano MC, Tavares R. Bioequiv alence evaluation of two omeprazole enteric-coated formulations in humans. Eur J Pharm Sci. 1999; Mar 7 (4) 311-5
• 10 Duvauchelle T, Milleroux L, Gualano V, Evene E, Alcaide A. Comparative bioavailability study of two oral omeprazole formulations after single and repeated administrations in healthy volunteers. Clin Drug Invest. 1998; 16 (2) 141-149
• 11 Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcao A, Silveira P, Almeida L. Soares-da-Silva R Bioavailability and bioequivalence of two enteric coated formulations of omeprazole in fasting and fed conditions. Clin Drug Invest. 2005; 25 (6) 391-399